International
The Morning Science

What science found today

‹
 

Release

FDA approves first factor XIa inhibitor for secondary stroke prevention

Medical Xpress ·

FDA approves first factor XIa inhibitor for secondary stroke prevention

The Brief

  • The FDA approved Sunharbo (asundexian) 50 mg tablets, taken with antiplatelet therapy, to reduce stroke risk in adults.
  • The approval covers adults after a recent mild-to-moderate noncardioembolic ischemic stroke or a high-risk transient ischemic attack.
  • Asundexian is described as the first factor XIa inhibitor approved by the FDA for secondary stroke prevention.

Why it matters

It adds a new anticoagulant-class drug targeting factor XIa for preventing a second stroke, a population with high recurrence risk, giving clinicians a new option alongside antiplatelet therapy.

Who’s affected

  • clinicians treating stroke and transient ischemic attack patients
  • patients with recent noncardioembolic ischemic stroke or high-risk TIA
  • pharmaceutical and regulatory professionals

The U.S. Food and Drug Administration has approved Sunharbo (asundexian) 50 mg tablets, in combination with antiplatelet therapy, to reduce the risk for stroke in adults following a recent mild-to-moderate noncardioembolic ischemic stroke or a high-risk transient ischemic attack…

Timeline

  1. FDA approval of Sunharbo (asundexian) 50 mg tablets for secondary stroke prevention reported by Medical Xpress

  2. Medical Xpress - latest medical and health news stories

    FDA approves first factor XIa inhibitor for secondary stroke prevention

How do you feel about this?

0 Comments

    FDA approves first factor XIa inhibitor for secondary stroke prevention – The Morning Science